ATTR-CM

Medication adherence is a critical aspect of treating patients with ATTR-CM and ensuring optimal outcomes. Research suggests that many patients with ATTR-CM are adherent to treatment with tafamidis, partly due to the availability of a one-tablet dose. Tafamidis is the first FDA-approved treatment for ATTR-CM that has been shown to help reduce disease progression and...

An early diagnosis of transthyretin amyloidosis (ATTR) is key for managing the disease and preventing costly complications. One study suggests that cardiovascular symptoms and increased hospitalizations are a potential way to identify the disease early. Transthyretin amyloidosis (ATTR) is a progressive condition characterized by the buildup of amyloid in the organs and tissues. It can...

Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are faced with different possibilities for treating their symptoms and underlying disease. However, treatment options may vary depending on the severity of the disease, the cost of the treatment, and other factors. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive disease that primarily affects the heart, although it can...

Transthyretin (TTR) gene variants may increase the risk of heart failure and other cardiac complications. A specific TTR gene variant at position 122 (V142I) is particularly common among middle-aged Black patients. The TTR V142I variant is characterized by a valine-to-isoleucine substitution and is a significant cause of cardiac amyloidosis. Although research is ongoing, one particular...

The cardiac presentation of transthyretin amyloidosis, otherwise known as transthyretin amyloid cardiomyopathy (ATTR-CM), can be life-threatening. Without proper support and treatment, ATTR-CM can cause heart failure (HF). Given the severe nature of the disease, patients with ATTR HF may experience higher costs of care than those with non-ATTR HF. This study, published in ESC Heart...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening heart condition historically considered a rare disease. Left untreated, ATTR-CM can lead to heart failure and other heart complications. Several mutations in the TTR gene are associated with the development of the disease. The V122I mutation is the most common variant in the United States, and around 4% of...

Wild-type transthyretin amyloidosis (ATTRwt) is a non-hereditary form of transthyretin amyloid cardiomyopathy (ATTR-CM) that commonly leads to peripheral neuropathy and carpal tunnel syndrome. The symptoms of ATTRwt usually do not appear until after 60 in men and women. However, what makes ATTRwt particularly dangerous is that it can remain undiagnosed, especially in women. Few studies...

The prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) is reportedly lower in women than men. As a life-threatening heart condition, ATTR-CM can often lead to heart failure and other complications, including death. However, sex-related differences have not been assessed in detail.  This systematic review, published in Heart Failure Reviews, sought to determine whether there are differences in...